These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 8808706)

  • 1. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
    Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
    Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells.
    Cao Y; Gao Q; Wazer DE; Band V
    Cancer Res; 1997 Dec; 57(24):5584-9. PubMed ID: 9407971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
    Willis A; Jung EJ; Wakefield T; Chen X
    Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour p53 mutations exhibit promoter selective dominance over wild type p53.
    Monti P; Campomenosi P; Ciribilli Y; Iannone R; Inga A; Abbondandolo A; Resnick MA; Fronza G
    Oncogene; 2002 Mar; 21(11):1641-8. PubMed ID: 11896595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
    Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
    Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant p53 proteins behave in a dominant, negative fashion in vivo.
    Hachiya M; Chumakov A; Miller CW; Akashi M; Said J; Koeffler HP
    Anticancer Res; 1994; 14(5A):1853-9. PubMed ID: 7847818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells.
    Katayose D; Gudas J; Nguyen H; Srivastava S; Cowan KH; Seth P
    Clin Cancer Res; 1995 Aug; 1(8):889-97. PubMed ID: 9816059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The p53 tumor suppressor gene and gene product.
    Levine AJ
    Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
    Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
    Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
    Liang Y; Wu J; Stancel GM; Hyder SM
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles.
    Rand A; Glenn KS; Alvares CP; White MB; Thibodeau SM; Karnes WE
    Cancer Lett; 1996 Jan; 98(2):183-91. PubMed ID: 8556707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of cell cycle, wild-type p53 and DNA damage on p21CIP1/Waf1 expression in human breast epithelial cells.
    Gudas J; Nguyen H; Li T; Hill D; Cowan KH
    Oncogene; 1995 Jul; 11(2):253-61. PubMed ID: 7624142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions.
    Negrini M; Sabbioni S; Haldar S; Possati L; Castagnoli A; Corallini A; Barbanti-Brodano G; Croce CM
    Cancer Res; 1994 Apr; 54(7):1818-24. PubMed ID: 8137297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
    de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions.
    Subler MA; Martin DW; Deb S
    Oncogene; 1994 May; 9(5):1351-9. PubMed ID: 8152795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wild-type p53 down-regulates transcription from oncogenic human papillomavirus promoters through the epithelial specific enhancer.
    Desaintes C; Hallez S; Detremmerie O; Burny A
    Oncogene; 1995 Jun; 10(11):2155-61. PubMed ID: 7784059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immortalization of human mammary epithelial cells transfected with mutant p53 (273his).
    Gollahon LS; Shay JW
    Oncogene; 1996 Feb; 12(4):715-25. PubMed ID: 8632893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p21(WAF1/CIP1) response to genotoxic agents in wild-type TP53 expressing breast primary tumours.
    Guillot C; Falette N; Paperin MP; Courtois S; Gentil-Perret A; Treilleux I; Ozturk M; Puisieux A
    Oncogene; 1997 Jan; 14(1):45-52. PubMed ID: 9010231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription.
    Miller CW; Chumakov A; Said J; Chen DL; Aslo A; Koeffler HP
    Oncogene; 1993 Jul; 8(7):1815-24. PubMed ID: 8510927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.